Gastrointestinal Cancer

Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.

Richard S. Finn, MD, reflects on data from the phase III REFLECT, RESORCE, CELESTIAL, and REACH-2 trials in hepatocellular carcinoma.

David J. Pinato, MD, PhD, highlights the clinical and biological challenges in identifying biomarkers in hepatocellular carcinoma, and the potential introduction of biomarkers in the future.

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Neehar Parikh, MD, discusses the importance of multidisciplinary care in the treatment of patients with hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

Findings from the phase III IMbrave 150 trial represented the first time a treatment outperformed sorafenib for overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC), and the HCC world was understandably excited, said Ghassan K. Abou-Alfa, MD.